These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 9555863)

  • 21. Atherogenic lipoprotein changes in the absence of hyperlipidemia in patients with chronic renal failure treated by hemodialysis.
    Shoji T; Nishizawa Y; Kawagishi T; Tanaka M; Kawasaki K; Tabata T; Inoue T; Morii H
    Atherosclerosis; 1997 Jun; 131(2):229-36. PubMed ID: 9199276
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Associations between lipoproteins and the progression of coronary and vein-graft atherosclerosis in a controlled trial with gemfibrozil in men with low baseline levels of HDL cholesterol.
    Syvänne M; Nieminen MS; Frick MH; Kauma H; Majahalme S; Virtanen V; Kesäniemi YA; Pasternack A; Ehnholm C; Taskinen MR
    Circulation; 1998 Nov; 98(19):1993-9. PubMed ID: 9808595
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Intermediate density lipoprotein levels are strong predictors of the extent of aortic atherosclerosis in the St. Thomas's Hospital rabbit strain.
    Nordestgaard BG; Lewis B
    Atherosclerosis; 1991 Mar; 87(1):39-46. PubMed ID: 1872923
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Efficacy and safety of long-term ezetimibe/simvastatin treatment in patients with familial hypercholesterolemia.
    Avellone G; Di Garbo V; Guarnotta V; Scaglione R; Parrinello G; Purpura L; Torres D; Campisi D
    Int Angiol; 2010 Dec; 29(6):514-24. PubMed ID: 21173733
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Dose-dependent action of atorvastatin in type IIB hyperlipidemia: preferential and progressive reduction of atherogenic apoB-containing lipoprotein subclasses (VLDL-2, IDL, small dense LDL) and stimulation of cellular cholesterol efflux.
    Guerin M; Egger P; Soudant C; Le Goff W; van Tol A; Dupuis R; Chapman MJ
    Atherosclerosis; 2002 Aug; 163(2):287-96. PubMed ID: 12052475
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A comparative study of the efficacy of simvastatin and gemfibrozil in combined hyperlipoproteinemia: prediction of response by baseline lipids, apo E genotype, lipoprotein(a) and insulin.
    Nestel P; Simons L; Barter P; Clifton P; Colquhoun D; Hamilton-Craig I; Sikaris K; Sullivan D
    Atherosclerosis; 1997 Mar; 129(2):231-9. PubMed ID: 9105566
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effects of long-term treatment with simvastatin on plasma lipids and lipoproteins in patients with primary hypercholesterolemia.
    Thiery J; Creutzfeldt C; Creutzfeldt W; Walli AK; Seidel D
    Klin Wochenschr; 1990 Aug; 68(16):814-22. PubMed ID: 2214604
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Benefits of early lipid-lowering intervention in high-risk patients: the lipid intervention strategies for coronary patients study.
    Pedersen TR; Jahnsen KE; Vatn S; Semb AG; Kontny F; Zalmai A; Nerdrum T
    Clin Ther; 2000 Aug; 22(8):949-60. PubMed ID: 10972631
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effects of adding fenofibrate (200 mg/day) to simvastatin (10 mg/day) in patients with combined hyperlipidemia and metabolic syndrome.
    Vega GL; Ma PT; Cater NB; Filipchuk N; Meguro S; Garcia-Garcia AB; Grundy SM
    Am J Cardiol; 2003 Apr; 91(8):956-60. PubMed ID: 12686335
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Treating patients with documented atherosclerosis to National Cholesterol Education Program-recommended low-density-lipoprotein cholesterol goals with atorvastatin, fluvastatin, lovastatin and simvastatin.
    Brown AS; Bakker-Arkema RG; Yellen L; Henley RW; Guthrie R; Campbell CF; Koren M; Woo W; McLain R; Black DM
    J Am Coll Cardiol; 1998 Sep; 32(3):665-72. PubMed ID: 9741509
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Independent associations between plasma lipoprotein subfraction levels and the course of coronary artery disease in the St. Thomas' Atherosclerosis Regression Study (STARS).
    Watts GF; Mandalia S; Brunt JN; Slavin BM; Coltart DJ; Lewis B
    Metabolism; 1993 Nov; 42(11):1461-7. PubMed ID: 8231842
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effect of dietary treatment on the lipid, lipoprotein and fatty acid compositions in type IV familial hypertriglyceridemia.
    Agheli N; Cloarec M; Jacotot B
    Ann Nutr Metab; 1991; 35(5):261-73. PubMed ID: 1776822
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Lipid lowering by simvastatin induces regression of human atherosclerotic lesions: two years' follow-up by high-resolution noninvasive magnetic resonance imaging.
    Corti R; Fuster V; Fayad ZA; Worthley SG; Helft G; Smith D; Weinberger J; Wentzel J; Mizsei G; Mercuri M; Badimon JJ
    Circulation; 2002 Dec; 106(23):2884-7. PubMed ID: 12460866
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The effect of simvastatin on progression of coronary artery disease. The Multicenter coronary Intervention Study (CIS).
    Bestehorn HP; Rensing UF; Roskamm H; Betz P; Benesch L; Schemeitat K; Blümchen G; Claus J; Mathes P; Kappenberger L; Wieland H; Neiss A
    Eur Heart J; 1997 Feb; 18(2):226-34. PubMed ID: 9043838
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Rationale and design features of a clinical trial examining the effects of cholesterol lowering and angiotensin-converting enzyme inhibition on coronary atherosclerosis: Simvastatin/Enalapril Coronary Atherosclerosis Trial (SCAT). SCAT Investigators.
    Teo KK; Burton JR; Buller C; Plante S; Yokoyama S; Montague TJ
    Can J Cardiol; 1997 Jun; 13(6):591-9. PubMed ID: 9215232
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Comparisons of effects of statins (atorvastatin, fluvastatin, lovastatin, pravastatin, and simvastatin) on fasting and postprandial lipoproteins in patients with coronary heart disease versus control subjects.
    Schaefer EJ; McNamara JR; Tayler T; Daly JA; Gleason JL; Seman LJ; Ferrari A; Rubenstein JJ
    Am J Cardiol; 2004 Jan; 93(1):31-9. PubMed ID: 14697462
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Comparison of rosuvastatin with atorvastatin, simvastatin and pravastatin in achieving cholesterol goals and improving plasma lipids in hypercholesterolaemic patients with or without the metabolic syndrome in the MERCURY I trial.
    Stender S; Schuster H; Barter P; Watkins C; Kallend D;
    Diabetes Obes Metab; 2005 Jul; 7(4):430-8. PubMed ID: 15955130
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Lipid-altering efficacy and safety of simvastatin 80 mg/day: long-term experience in a large group of patients with hypercholesterolemia. World Wide Expanded Dose Simvastatin Study Group.
    Ose L; Davidson MH; Stein EA; Kastelein JJ; Scott RS; Hunninghake DB; Campodonico S; Insull W; Escobar ID; Schrott HG; Stepanavage ME; Wu M; Tate AC; Melino MR; Mercuri M; Mitchel YB
    Clin Cardiol; 2000 Jan; 23(1):39-46. PubMed ID: 10680028
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Intensive lipid-lowering strategy in patients with diabetes mellitus.
    Kanters SD; Algra A; de Bruint TW; Erkelens DW; Banga JD
    Diabet Med; 1999 Jun; 16(6):500-8. PubMed ID: 10391399
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Long-term effects of cholesterol lowering and angiotensin-converting enzyme inhibition on coronary atherosclerosis: The Simvastatin/Enalapril Coronary Atherosclerosis Trial (SCAT).
    Teo KK; Burton JR; Buller CE; Plante S; Catellier D; Tymchak W; Dzavik V; Taylor D; Yokoyama S; Montague TJ
    Circulation; 2000 Oct; 102(15):1748-54. PubMed ID: 11023927
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.